Diamics Inc.
This article was originally published in Start Up
Executive Summary
Pap smears for women are a necessary evil. Early screening is a key reason the number of cervical cancer deaths in developed countries is so much lower than elsewhere in the world. Now, Diamics hopes to offer a molecular diagnostic for cervical cancer at the point-of-care.
You may also be interested in...
Women's Health: A Growing Market for Diagnostic Players
Women's health is an area long shunned by pharmaceutical and diagnostic companies. But that is starting to change thanks to the successes of companies such as Cytyc and Digene, who have built successful testing franchises in the Ob/ Gyn market. As companies such as PerkinElmer and others look to develop new tests in this market, a spate of start-ups are developing technologies that might fit the bill. Of greatest interest are the so-called molecular tests since they offer the advantage of premium pricing.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.